OnKure Therapeutics (OKUR) Total Current Liabilities (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Total Current Liabilities came in at $14.3 million in Q1 2026, up 63.11% YoY from $8.8 million in Q1 2025, and up 142.0% on a QoQ basis from $5.9 million in Q4 2025.
OnKure Therapeutics (OKUR) Total Current Liabilities (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Total Current Liabilities data on file, last reported at $14.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 63.11% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 63.11% YoY) and the FY2025 annual result came in at $5.9 million, down 43.77% from the prior year.
- Total Current Liabilities climbed to $14.3 million in Q1 2026, from $5.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $14.3 million in Q1 2026 to a low of $1.3 million in Q2 2024.
- A 5-year average of $8.2 million and a median of $7.9 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 90.19% — and 2025, when it jumped 463.58%.
- Tracing OKUR's Total Current Liabilities over 5 years: stood at $7.1 million in 2022, then rose by 2.26% to $7.3 million in 2023, then soared by 44.54% to $10.5 million in 2024, then slumped by 43.77% to $5.9 million in 2025, then surged by 142.0% to $14.3 million in 2026.
- The last three Total Current Liabilities figures came in at $14.3 million (Q1 2026), $5.9 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 6.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.64 Mn |
| Mar 31, 2026 | 14.33 Mn |
| Dec 31, 2025 | 5.92 Mn |
| Sep 30, 2025 | 6.25 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Mar 31, 2025 | 8.79 Mn |
| Dec 31, 2024 | 10.53 Mn |
| Sep 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 2.81 Mn |
| Dec 31, 2023 | 7.29 Mn |
| Sep 30, 2023 | 13.56 Mn |
| Jun 30, 2023 | 13.74 Mn |
| Mar 31, 2023 | 10.48 Mn |
| Dec 31, 2022 | 7.12 Mn |
| Sep 30, 2022 | 9.45 Mn |
| Jun 30, 2022 | 8.34 Mn |
| Mar 31, 2022 | 7.91 Mn |
| Dec 31, 2021 | 6.20 Mn |
| Sep 30, 2021 | 6.35 Mn |